Products for Research Use Only
RegisterLogin

SNDX-5613

CAT: 0013-GTR19156024-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19156024-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SNDX-5613 is a potent and specific inhibitor of Menin-MLL (Ki of 0.149 nM and a cell based IC50 of 10-20 nM) . SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo) :Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
CAS Number
2169919-21-3
Purity
>98% (HPLC)
Solubility
DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)
Smiles
O=C (C1=CC (F) =CC=C1OC2=CN=CN=C2N3CC4 (C3) CCN (CC4) C[C@H]5CC[C@@H] (CC5) NS (=O) (CC) =O) N (C (C) C) CC
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.

Related Products

CatalogName
GTR19208866-01SU 5616
GTR18024265Snd1 Antibody
GTR18062548-01SND1 antibody
GTR18569088SND1 Antibody
GTR18583753-01SND1 Antibody
GTR18896965-01SND1 peptide
GTR17885540-01SND1 Antibody
GTR18591160-01SND1 Antibody
GTR18014248SND1 Antibody
GTR18072674SND1 Antibody

Alternative Products

CatalogName
MBS5753933SNDX-5613
A22526-5SNDX-5613 5mg
S8996-5mgRevumenib (SNDX-5613)
A22526-100SNDX-5613 100mg
A22526-50SNDX-5613 50mg
A22526-10SNDX-5613 10mg
C21534-1gSNDX-5613 (Revumenib)
A22526-2Revumenib (SNDX-5613) 2mg
A22526-1Revumenib (SNDX-5613) 1mg
A22526-25Revumenib (SNDX-5613) 25mg

Popular Products